NCT05312424 (GG-statin) is a Phase 1, PHASE2 clinical trial of Low GG in Myopathy; Primary, sponsored by Texas Tech University Health Sciences Center.

Who is sponsoring NCT05312424?

NCT05312424 is sponsored by Texas Tech University Health Sciences Center.

What drugs are being tested in NCT05312424?

Interventions in NCT05312424: Placebo, Low GG, High GG.

What condition does NCT05312424 study?

NCT05312424 studies Myopathy; Primary.

Is NCT05312424 still recruiting?

NCT05312424 is currently recruiting now. Last updated 12 September 2025.

Last reviewed 2025-09-12 · How we verify

NCT05312424: GG-statin

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Annatto-derived GG for Statin-associated Myopathy

Recruiting now Phase 1, PHASE2 Last updated 12 September 2025

What this trial tests

Phase 1, PHASE2 trial testing Placebo in Myopathy; Primary in 95 participants. Currently enrolling.

Timeline

15 July 2022

Primary endpoint
30 June 2027

31 December 2027

Quick facts

Lead sponsor	Texas Tech University Health Sciences Center
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	95
Start date	15 July 2022
Primary completion	30 June 2027
Estimated completion	31 December 2027
Sites	1 location across United States

Drugs / interventions tested

Placebo
Low GG
High GG

Conditions studied

Myopathy; Primary — all drugs for Myopathy; Primary →

Sponsor

Texas Tech University Health Sciences Center

Who can join

40 and older, any sex, with Myopathy; Primary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the effects of 3-months annatto-derived geranylgeraniol (GG) supplementation on statin-associated skeletal muscle health.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Texas Tech University Health Sciences Center trials

Trials by the same sponsor.

NCT07348406 — Snacks and Brain Health · Phase 1, PHASE2 · not yet recruiting
NCT07407426 — EEG-Guided Binaural Beat Audio to Reduce Performance-Related Stress and Improve Cognition · NA · not yet recruiting
NCT07434375 — Speech Intervention Via Telepractice for Children With Repaired Cleft Palate · NA · not yet recruiting
NCT07451210 — Evaluating the Efficacy of Blood Flow Restriction Therapy in a Randomized Clinical Trial for Postoperative Rehabilitatio · NA · recruiting
NCT07309874 — Effect of Ultrasound-Guided Dry Needling Targeting Rectus Capitus Posterior Major on Individuals With Headaches · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05312424 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Texas Tech University Health Sciences Center
Last refreshed: 12 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05312424.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing